Release of interleukin-1 beta (IL-1β) is a significant risk factor in cardiovascular disease (e.g., 2 atherosclerosis). Tumor necrosis factor alpha (TNF) promotes IL-1β release, associated with 3 purinergic signaling and increased intracellular Ca 2+ , although the pathways controlling these 4 have not been described. TNF is known to promote opening of the endothelial pannexin 1 (Panx1) 5 membrane channel, allowing for ATP release, associated with inflammatory cell recruitment.
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In Brief 1 Interleukine-1 beta (IL-1β) has been identified as a critical factor that contributes to the 2 inflammatory response in cardiovascular disease (e.g., atherosclerosis). Pannexin 1 (Panx1) 3 channel activity in endothelial cells regulates localized inflammatory cell recruitment. In response 4 to prolonged tumor necrosis factor alpha (TNF) treatment, Yang et al. found that the Panx1 5 channel is targeted to the plasma membrane, where it facilitates an increase in intracellular 6 calcium to control the production and release of cytokines including IL-1β. In human umbilical vein endothelial cells (HUVECs), we initially demonstrate that prolonged 3 exposure to TNF (2.5ng/mL) for 5 hr and 24 hr leads to an increase in the transcription of Panx1, 4 measured by qRT-PCR ( Figure 1A) . Increases in Panx1 mRNA levels correlate with significant 5 increases in protein expression of Panx1 at 5 hr, measured by immunoblotting ( Figure 1B) . The 6 multiple banding pattern for the Panx1 protein observed in immunoblots represents differential al., 2008) . Interestingly, we observed that, at 5 hr, 9 TNF treatments primarily increase only Panx1-Gly0 and Panx1-Gly1 isoforms, which were ablated 10 by co-treatment with the protein synthesis inhibitor cycloheximide (CHX, Figure 1B and 11 Supplemental Figure 1A ), suggesting that these isoforms represent newly synthesized Panx1.
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To determine the specificity of TNF to Panx1 expression, we investigated the Cx43 gap junction 13 protein in HUVECs, which did not increase following TNF stimulation and was inhibited following 14 CHX treatments (Figure 1B) . Following 24 hr TNF treatment, we identified significant upregulation 15 of the Panx1-Gly2 isoform (Supplemental Figure 1B) . Increasing the concentration of TNF 16 treatments did not enhance Panx1 expression from 2.5 ng/mL at either 5 hr or 24 hr and did not 17 alter expression of Cx43 (Supplemental Figure 1A-C ). In addition, Panx1-Gly2 isoforms were 18 not reduced by CHX (Figure 1B ), suggesting that these represent a more stable isoform of Panx1.
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To investigate this, HUVECs were treated with TNF for 24 hr, washed in fresh media without TNF, 20 and cultured for a further 8 days. Analysis by immunoblot demonstrates that while the Panx1-
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Gly0/1 isoforms are lost within 24 hr of removal of TNF, the Panx1-Gly2 isoforms remain 22 significantly increased from control for 24 hr after removal of TNF and remain elevated for a further 23 5 days ( Figure 1C ). This demonstrates a stable, mature form of Panx1 that has a significant 24 residence time at the plasma membrane, making it more stable than connexin proteins.
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Previous studies have suggested that Panx1-Gly2 isoforms represent the mature Panx1 channels 26 within the plasma membrane (Boassa et al., 2007) . We therefore used a membrane protein 27 biotinylation pull-down approach to isolate plasma membrane proteins and identified that Panx1-
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Gly2 isoforms are primarily localized within the plasma membrane 24 hr after TNF treatment 29 ( Figure 1D ). We further demonstrate that Panx1 expression by cultured human vascular smooth 30 muscle cells (SMC) is unaltered by TNF treatment (Supplemental Figure 1D) . Previous studies 31 have found TNF to reduce cell viability (Zhou et al., 2017). However, 24 hr TNF treatments ranging 7 from 2.5-100 ng/mL for 24 hr did not alter HUVEC viability as measured by intracellular ATP 1 levels, caspase-3 cleavage, or by cell morphology (Supplemental Figure 1E -G).
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TNF signaling is associated with activation of NFκβ-mediated gene regulation. Whole-3 transcriptome RNA sequencing (RNA-seq) experiments confirmed that TNF treatment of HUVEC 4 significantly upregulated NFκβ genes NFKBIA, NFKBIE, NFKB1, NFKB2, NFKB1B (Figure 1E) .
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To define a role for NFκβ-activated pathways in TNF-induced increases in Panx1 expression,
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HUVECs were pre-treated with NFκβ-inhibitors SC514 and QNZ. Both SC514 and QNZ, 16 Sharma et al., 2018). To investigate whether the increased Panx1 at the plasma membrane is 17 directly associated with cytokine production and release, we first used genetic inhibition of Panx1.
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Panx1-siRNA reduced the basal expression of Panx1 in HUVECs and inhibited increases in 19 Panx1 in response to TNF (Figure 2A-B) . Cytokine arrays used to assay the media from HUVEC 20 cells showed that TNF treatment altered the expression of a number of cytokines (Supplemental 21 Figure 2 ). We selected key pro-inflammatory cytokines associated with atherosclerosis such as 22 IL-1β and CXCL10, IL8 and CCL2 which were found to be increased in response to TNF treatment 23 in HUVEC, unlike MIF and CD147 which were not markedly increased by TNF ( Figure 2C) . siRNA 24 knockdown of Panx1 in HUVECs was associated with a reduction in the release of IL-1β and 25 CXCL10 (Figure 2C, Supplemental Figure 2) . Notably, Panx1 siRNA treated cells displayed a 26 significantly reduced transcription of IL-1β and CXCL10 but showed no differences in IL8 and 27 CCL2 (Figure 2D-E) . Panx1 siRNA and TNF-treatments also had no effect on MIF or CD147 28 ( Figure 2F) . These data suggest that Panx1 critically regulates the control of specific 
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Purinergic signaling is not a key regulator of TNF-induced IL-1β in endothelial cells. Based 5 on the known role for Panx1 and ATP release, which has been linked with IL-1β regulation, we 6 investigated ATP release from HUVECs following treatment with TNF and the corresponding 7 effects of ATP on IL-1β. ATP release from HUVECs was measured in media following TNF 8 treatment at doses ranging from 2.5-100 ng/mL. All concentrations of TNF produced similar 9 increases in ATP release from HUVECs (Figure 3A) , which was significantly reduced following 10 genetic inhibition of Panx1 ( Figure 3B) . While previous studies have correlated ATP treatment 11 with regulation of IL-1β, this has typically required ATP analogues to be applied at concentrations ). Our data demonstrate that the HUVECs release only 10-20 nM ATP once exposed to TNF
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(2.5 ng/mL) for 24 hr (Figure 3C ). At these concentrations (10 nM -100 μM ), the ATP analogue 15 ATPγS failed to increase IL-1β transcription (Figure 3D ). However, we did observe a small 16 increase in transcription of IL-1β at 100 μM ATPγS, which could be ablated by pre-treating cells 17 with the P2X inhibitor suramin ( Figure 3E ). Further data demonstrate that promoting the 18 degradation of released ATP using apyrase or inhibition of the P2 receptors using suramin, did 19 not significantly alter the expression of either Panx1 or IL-1β in the presence of TNF (Figure 3F -20 G). Thus, the NFκβ-induced increase in Panx1 expression at the plasma membrane, while crucial 21 for IL-1β cytokine production, was not regulated by an autocrine ATP release from the EC.
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TNF increases in intracellular Ca 2+ which is regulated by the functional Panx1 channels.
23
Increased intracellular Ca 2+ is associated with the control of IL-1β synthesis (Ainscough et al., that Panx1 channels in the plasma membrane act as a conduit for the movement of Ca 2+ into the 20 cytosol, leading to activation of NFκβ signaling, which acts as a feed-forward mechanism to 21 promote the production and release of IL-1β. Panx1-mediated mechanisms controlling inflammation have never been fully elucidated. Here we 5 demonstrate that EC-Panx1 is a direct target of the TNF signaling pathway, promoting plasma 6 membrane localization of the channel, which facilitates the entry of extracellular Ca 2+ into the 7 cytosol. Importantly, we show that increases in intracellular Ca 2+ , resulting from enhanced Panx1 8 channel activity are directly associated with upregulated transcription and release of pro-9 inflammatory cytokines including IL-1β.
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One of the primary findings in this study is the identification of a novel mechanism for the 11 transcriptional regulation of Panx1. We observed that EC Panx1 is acutely sensitive to TNF 12 stimulation, with maximal increases found in the low ng/mL range. Our data suggest that this is 13 not a ubiquitous pathway, as increases in Panx1 expression were not found in TNF-treated SMCs 32 11 We also found that increases in Panx1-transcription are followed by protein translation within 5 1 hours that was lost when cells were treated with the protein synthesis inhibitor CHX. The newly 2 synthesized Panx1 proteins then translocate to the plasma membrane within 24 hours. Our 3 surface biotinylation experiments highlight that the Panx1 isoform at the plasma membrane is 4 primarily the complex-glycoprotein isoform (Panx1-Gly2). This is in keeping with previous studies 5 suggesting that the Panx1-Gly2 is the predominant post-translationally modified form of Panx1 in 
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This has led to the suggestion that atherosclerosis may be under the control of IL-1β and that 29 targeting pathways controlling or controlled by IL-1β may have therapeutic benefit (Brown et al., Hansson, 2015; Ridker, 2013, 2019). However, the mechanisms through which Panx1 regulates 10 these cytokines and chemokines remain to be fully elucidated.
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The primary focus for signaling via Panx1 channels has been the release of ATP following channel ). In keeping with these observations, we found that treatment of 28 HUVECs with 100 μM ATP-γS did induce an increase IL-1β transcription, that was inhibited by 29 the P2X inhibitor suramin. However, it should be noted that the ATP-induced IL-1β responses 30 were significantly lower than those following TNF stimulation in our study. Furthermore, TNF-31 induced IL-1β and Panx1 expression in HUVECs was not altered by co-treatment with apyrase 32 (to degrade ATP) or in the presence of suramin (to block P2X receptors). Taken together, these 33 13 data suggest that ATP is not the primary mechanism for alterations in IL-1β synthesis in HUVECs 1 following TNF treatment. , 2006) . Here, we found that [Ca 2+ ]i was increased in 5 HUVEC cells in response to TNF. Interestingly, this did not occur at earlier timepoints (5 hr) 6 suggesting that kinase activation of TNF pathways is not involved. Rather, increases in 7 intracellular Ca 2+ were only found after long-term stimulation of up to 24 hr, a timepoint at which 8 we demonstrate Panx1 channels are functional at the plasma membrane. To assess the source 9 of increased intracellular Ca 2+ we repeated the TNF stimulation experiment in Ca 2+ free Krebs 10 solution, which blocked the response, suggesting that increases in intracellular Ca 2+ originated 11 from outside the cell. While it is possible that other mechanisms serve to facilitate the entry of 12 Ca 2+ under these conditions, we provide several lines of evidence that suggest that Panx1 13 channels are directly permeable to Ca 2+ , these include no Ca 2+ response to TNF when Panx1 is 14 silenced by siRNA or the channel is inhibited using the Panx1 specific inhibitor peptide PxIL2P.
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Our data show that increases in intracellular Ca 2+ are associated with IL-1β -synthesis, that can 16 be ablated following reductions in intracellular Ca 2+ using EGTA-AM and by blocking the Panx1 17 channel. Our data therefore suggest that plasma membrane Panx1 channels are permeable to, 18 and facilitate increases in [Ca 2+ ]i.
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The NFκβ-p65 protein, is a downstream target of TNF signaling, and blocking its activation 
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Immunoblotting and membrane protein biotinylation
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Following treatments, all cells were harvested in cold lysis containing PBS (pH 7.4) containing:
22 NaCl (125 mM); EDTA (5 mM); sodium deoxycholate (1%); triton X-100 (0.5%); sodium 23 orthavanadate (500 μM); AEBSF (10 μM) and protease inhibitor cocktail (1:100, Sigma). All 
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